miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA)

Zheng, Bo; Jeong, Seogsong; Zhu, Yanjing; Chen, Lei; Xia, Qiang

doi:10.18632/oncotarget.19044

Cited by 51 publications

(40 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMB is correlated with clinical outcome in multiple cancer types treated with CPI (65,66). Previous studies indicated that TMB levels correlated with gene mutations in tumors (25,40,67,68). TMB-H has been reported to correlate with the generation of neoantigens and potential clinical responses to immunotherapies (69).…”

Section: Discussionmentioning

confidence: 99%

“…The alignment of the sequences from tumor tissue samples and matched blood samples were considered to be an effective method for detecting somatic mutations (22)(23)(24). To date, many studies on potential biomarkers for CCA have been reported (25)(26)(27). Ong et al (28) identified and validated 206 somatic mutations in 187 genes, including somatic mutations in 10 newly implicated genes, using Sanger sequencing.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive genomic profile of cholangiocarcinomas in China

Shi

Liu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a primary malignancy, which is often diagnosed as locally advanced or metastatic. Previous studies have revealed genomic characteristics of CCA in Western patients, however comprehensive genomic features of CCA in Chinese patients have not been well understood. To explore the specific genomic characteristics of Chinese patients with CCA, a total of 66 patients with CCA, including 44 intrahepatic CCA (iCCA) and 22 extrahepatic CCA (exCCA) cases, were studied. The most commonly altered genes in CCAs were TP53 (62.12%, 41/66), KRAS (36.36%, 24/66), SMAD4 (24.24%, 16/66), TERT (21.21%, 14/66), ARID1A (19.70%, 13/66), CDKN2A (19.70%, 13/66), KMT2C (9.09%, 6/66) and RBM10 (9.09%, 6/66), ERBB2 (7.58%, 5/66) and BRAF (7.58%, 5/66). Many gene mutations, including STK11, CCND1 and FGF19, were only found in iCCA. RBM10 mutations were found to be significantly higher in exCCA. The gene mutations of neurofibromin 1, STK11, CCND1 and FBXW7 specifically occurred in males, whereas gene mutations of ERBB2, AXIN2 and CREBBP specifically occurred in females. ERBB2 mutations were significantly associated with the sex of patients with CCA. Mutations in PIK3CA, FGFR2 and ZNF750 were significantly associated with the age of patients with CCA and TERT mutations were significantly associated with tumor differentiation. Alterations in KMT2C, PBRM1, AXIN2, MAGI2, BRCA2 and SPTA1 were associated with tumor mutational burden. The findings of the present study suggest that targeted sequencing, using next-generation sequencing technology, provides comprehensive and accurate information on genomic alterations, which will provide novel potential biomarkers for the diagnosis of CCA and may guide precise therapeutic strategies for Chinese patients with CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comprehensive genomic profile of cholangiocarcinomas in China

Shi

Liu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…[12][13][14][15][16] Nevertheless, none of these has been convincingly validated and the power of single factors in predicting survival is limited. 17,18 Additionally, growing research interest is headed to novel biomarkers with potential predictive and prognostic value such as non-coding RNAs and exosomal proteins, [19][20][21] though this research field is still in its infancy. Hence, there remains an unmet need for a more accurate patients' stratification to inform clinical decision making as well as a rationale trials design.…”

Section: Backg Rou N Dmentioning

confidence: 99%

The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer

Salati

Filippi

Vivaldi

et al. 2019

Liver International

View full text Add to dashboard Cite

Background An accurate risk‐stratification is key to optimize the benefit‐to‐risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing the impact of the prognostic nutritional index (PNI) on survival and treatment response in advanced biliary cancer (ABC) receiving first‐line chemotherapy. Methods Medical records of ABC treated with standard chemotherapy at the Modena Cancer Centre were retrospectively reviewed for variables deemed of potential interest, including the PNI. Univariate and multivariate analyses were performed to investigate the association between the covariates and overall survival (OS). Results 114 ABC fulfilled the inclusion criteria and made up the training cohort. A PNI cut‐off value of 36.7 was established using the receiver operating characteristic (ROC) analysis. At both the univariate and the multivariate analysis, low PNI value (<36.7) was associated with shorter OS (P = .0011), together with increased NLR (P = .0046) and ECOG >1 (P < .0001). The median OS was 5.4 vs 12.1 months in the low‐ vs high PNI‐group. Moreover, a PNI value >36.7 resulted in a higher disease control in patients treated with gemcitabine/platinum combination (61.4% vs 34.3%). These results were validated in an independent cohort of 253 ABC. Conclusions We demonstrated and externally validated a prognostic role for the PNI in ABC treated with first‐line chemotherapy. Although the PNI turned out to be predictive in the subset of patients receiving platinum/gemcitabine combination, future prospective confirmation is needed.

show abstract

“…Aberrant transcriptomic change would occur subsequent to genetic and epigenetic modifications. Previous studies have confirmed the abnormal microRNA profiles in both CCA tumor tissues and cell lines . Mass spectrometry (MS)‐based proteomics has become a useful tool for the analysis of different biofluids to find accurate and specific protein biomarkers for risk stratification, diagnosis, and prognosis .…”

Section: Introductionmentioning

confidence: 98%

“…Previous studies have confirmed the abnormal microRNA profiles in both CCA tumor tissues and cell lines. [14][15][16] Mass spectrometry (MS)-based proteomics has become a useful tool for the analysis of different biofluids to find accurate and specific protein biomarkers for risk stratification, diagnosis, and prognosis. 17 Studies focused on proteomics have identified a specific peptide, SSP411 protein, in bile and urine showed better diagnostic value than the general non-specific tumor markers used in serum.…”

Section: Introductionmentioning

confidence: 99%

Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis

Tian¹,

Pu²,

Li³

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

AimCholangiocarcinoma (CCA) is a highly malignant tumor found in the bile duct epithelial cells, and the second most common primary tumor of the liver. However, the pivotal roles of molecular biomarkers in oncogenesis of CCA are unclear. Therefore, we aim to explore the underlying mechanisms of progression and screen for novel prognostic biomarkers and treatment targets.MethodThe data of mRNA sequencing and clinical information of CCA patients in The Cancer Genome Atlas was analyzed by weighted gene coexpression network analysis (WGCNA). Modules and clinical traits were constructed according to Pearson's correlation analysis, and Gene Ontology and pathway enrichment analysis were applied. Hub genes of these modules were screened by intramodule analysis; Cytoscape with Search Tool for the Retrieval of Interacting Genes was utilized to visualize protein–protein interaction of these modules; hub genes of these modules were validated afterwards. Furthermore, the significance of these genes was confirmed by survival analysis.ResultsGenes MRPS18A, CST1, and SCP2 were identified as candidate genes in the module, which was associated with clinical traits including pathological stage, histological grade, and liver function and which also affected overall survival of CCA patients. Nineteen hub genes were analyzed together and were associated with progression and prognosis of CCA. Survival analyses found that several of the multiple genes could serve as biomarkers to stratify CCA patients into low‐ and high‐risk groups.ConclusionThese candidate genes could be involved in progression of CCA, which could serve as novel prognostic markers and treatment targets. Moreover, most of them were first reported in CCA and deserve further research.

show abstract

miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA)

Cited by 51 publications

References 113 publications

Comprehensive genomic profile of cholangiocarcinomas in China

Comprehensive genomic profile of cholangiocarcinomas in China

The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer

Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis

Contact Info

Product

Resources

About